Glucocorticoid-Induced Autophagy in Osteocytes

Glucocorticoid (GC) therapy is the most frequent cause of secondary osteoporosis. In this study we have demonstrated that GC treatment induced the development of autophagy, preserving osteocyte viability. GC treatment resulted in an increase in autophagy markers and the accumulation of autophagosome vacuoles in vitro and in vivo promoted the onset of the osteocyte autophagy, as determined by expression of autophagy markers in an animal model of GC‐induced osteoporosis. An autophagy inhibitor reversed the protective effects of GCs. The effects of GCs on osteocytes were in contrast to tumor necrosis factor α (TNF‐α), which induced apoptosis but not autophagy. Together this study reveals a novel mechanism for the effect of GC on osteocytes, shedding new insight into mechanisms responsible for bone loss in patients receiving GC therapy. © 2010 American Society for Bone and Mineral Research.

[1]  Robert Clarke,et al.  Guidelines for the use and interpretation of assays for monitoring autophagy , 2012 .

[2]  D. Das,et al.  Is autophagy a double-edged sword for the heart? , 2009, Acta physiologica Hungarica.

[3]  N. Lane,et al.  Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. , 2008, Arthritis and rheumatism.

[4]  K. Tracey,et al.  HMGB1 is a bone‐active cytokine , 2008, Journal of cellular physiology.

[5]  Daniel J. Klionsky,et al.  Autophagy fights disease through cellular self-digestion , 2008, Nature.

[6]  John L Cleveland,et al.  Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes , 2008, Autophagy.

[7]  A. Parfitt,et al.  Perspective: Quantifying Osteoblast and Osteocyte Apoptosis: Challenges and Rewards , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  F. Behar-Cohen,et al.  Glucocorticoids induce retinal toxicity through mechanisms mainly associated with paraptosis. , 2007, Molecular vision.

[9]  Guido Kroemer,et al.  Self-eating and self-killing: crosstalk between autophagy and apoptosis , 2007, Nature Reviews Molecular Cell Biology.

[10]  P. Hulley,et al.  Vanadate prevents glucocorticoid-induced apoptosis of osteoblasts in vitro and osteocytes in vivo , 2007, The Journal of endocrinology.

[11]  B. Aggarwal,et al.  Evidence That Curcumin Suppresses the Growth of Malignant Gliomas in Vitro and in Vivo through Induction of Autophagy: Role of Akt and Extracellular Signal-Regulated Kinase Signaling Pathways , 2007, Molecular Pharmacology.

[12]  N. Mizushima,et al.  How to Interpret LC3 Immunoblotting , 2007, Autophagy.

[13]  M. Balooch,et al.  Glucocorticoid‐Treated Mice Have Localized Changes in Trabecular Bone Material Properties and Osteocyte Lacunar Size That Are Not Observed in Placebo‐Treated or Estrogen‐Deficient Mice , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  Y. Tsujimoto,et al.  Another way to die: autophagic programmed cell death , 2005, Cell Death and Differentiation.

[15]  L. Bonewald,et al.  Mechanical strain opens connexin 43 hemichannels in osteocytes: a novel mechanism for the release of prostaglandin. , 2005, Molecular biology of the cell.

[16]  P. Härkönen,et al.  Estrogen protects primary osteocytes against glucocorticoid-induced apoptosis , 2005, Apoptosis.

[17]  D. Granville,et al.  Detection of apoptosis in cardiovascular diseases. , 2005, Methods in molecular medicine.

[18]  R. Weinstein,et al.  Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. , 2004, Endocrinology.

[19]  I. Germano,et al.  Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells , 2004, Cell Death and Differentiation.

[20]  M. Matsui,et al.  In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. , 2003, Molecular biology of the cell.

[21]  J. Mao,et al.  Molecular mechanism of RU 486 action: a review , 1992, Molecular and Cellular Biochemistry.

[22]  E. Canalis.  Mechanisms of glucocorticoid action in bone , 2005, Annals of the New York Academy of Sciences.

[23]  C. Cooper,et al.  Use of Inhaled Corticosteroids and Risk of Fractures , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  Takeshi Noda,et al.  LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing , 2000, The EMBO journal.

[25]  D. Klionsky,et al.  Autophagy, cytoplasm-to-vacuole targeting pathway, and pexophagy in yeast and mammalian cells. , 2000, Annual review of biochemistry.

[26]  P. Roberson,et al.  Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. , 1999, The Journal of clinical investigation.

[27]  G. Gronowicz,et al.  Printed in U.S.A. Copyright © 1999 by The Endocrine Society Estrogen Prevents Glucocorticoid-Induced Apoptosis in , 2022 .

[28]  G. Gronowicz,et al.  Estrogen prevents glucocorticoid-induced apoptosis in osteoblasts in vivo and in vitro. , 1999, Endocrinology.

[29]  A. Parfitt,et al.  Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. , 1998, The Journal of clinical investigation.

[30]  H. Elsässer,et al.  Monodansylcadaverine (MDC) is a specific in vivo marker for autophagic vacuoles. , 1995, European journal of cell biology.

[31]  J. Kanis.  Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism , 1994 .

[32]  K. Horwitz,et al.  The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? , 1992, Endocrine reviews.